Benzinga | Aug 6, 2020 04:50PM EDT

Spero Therapeutics Q2 EPS $(0.85) Beats $(1.12) Estimate, Sales $1.73M Miss $3.40M Estimate

Spero Therapeutics (NASDAQ:SPRO) reported quarterly losses of $(0.85) per share which beat the analyst consensus estimate of $(1.12) by 24.11 percent. This is a 14.86 percent decrease over losses of $(0.74) per share from the same period last year. The company reported quarterly sales of $1.73 million which missed the analyst consensus estimate of $3.40 million by 49.21 percent. This is a 19.90 percent decrease over sales of $2.16 million the same period last year.